Showing results (61-70 of 204) with videos related to
Sort By:
Pageof 21
Blood|March 17, 2016
The 2016 revision of the World Health Organization classification of lymphoid neoplasmsSteven H Swerdlow, Elias Campo, Stefano A Pileri, et al.British Journal of Haematology|April 9, 2015
Disease characteristics, treatment patterns, prognosis, outcomes and lymphoma-related mortality in elderly follicular lymphoma in the United StatesChadi Nabhan, Michelle Byrtek, Ashish Rai, et al.British Journal of Haematology|February 6, 2016
The potential benefit of allogeneic over autologous transplantation in patients with very early relapsed and refractory follicular lymphoma with prior remission duration of ≤12 monthsMatthew A Lunning, Jocelyn C Migliacci, Patrick Hilden, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 28, 2005
Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomasRichard I Fisher, Mark S Kaminski, Richard L Wahl, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 8, 2006
Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemiaNicole Lamanna, Matt Kalaycio, Peter Maslak, et al.The Lancet. Oncology|July 14, 2022
Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: a multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trialJohn M Pagel, Jacob D Soumerai, Nishitha Reddy, et al.Leukemia & Lymphoma|November 9, 2018
Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trialsJacob D Soumerai, Ai Ni, Guan Xing, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 5, 2008
Comparison of referring and final pathology for patients with non-Hodgkin's lymphoma in the National Comprehensive Cancer NetworkAnn S LaCasce, Michelle E Kho, Jonathan W Friedberg, et al.Blood|April 5, 2003
Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphomaPaul A Hamlin, Andrew D Zelenetz, Tarun Kewalramani, et al.Leukemia & Lymphoma|November 22, 2011
High rates of surveillance imaging for treated diffuse large B-cell lymphoma: findings from a large national databaseGregory A Abel, Ann Vanderplas, Maria A Rodriguez, et al.Pageof 21